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Abstract
Background: Colorectal cancer is a major contributor to cancer morbidity and mortality. Tandem repeat instability
and its effect on cancer phenotypes remain so far poorly studied on a genome-wide scale.
Results: Here we analyze the genomes of 35 colorectal tumors and their matched normal (healthy) tissues for
two types of tandem repeat instability, de-novo repeat gain or loss and repeat copy number variation. Specifically, we
study for the first time genome-wide repeat instability in the promoters and exons of 18,439 genes, and examine the
association of repeat instability with genome-scale gene expression levels. We find that tumors with a microsatellite
instable (MSI) phenotype are enriched in genes with repeat instability, and that tumor genomes have
significantly more genes with repeat instability compared to healthy tissues. Genes in tumor genomes with repeat
instability in their promoters are significantly less expressed and show slightly higher levels of methylation. Genes in
well-studied cancer-associated signaling pathways also contain significantly more unstable repeats in tumor genomes.
Genes with such unstable repeats in the tumor-suppressor p53 pathway have lower expression levels, whereas genes
with repeat instability in the MAPK and Wnt signaling pathways are expressed at higher levels, consistent with the
oncogenic role they play in cancer.
Conclusions: Our results suggest that repeat instability in gene promoters and associated differential gene expression
may play an important role in colorectal tumors, which is a first step towards the development of more effective
molecular diagnostic approaches centered on repeat instability.
Keywords: Tandem repeats, Colorectal cancer, MSI, Microsatellite instability, Expression, Repeat instability, Microsatellite,
Cancer pathways, Cancer genes, Wnt signaling pathway, p53 pathway, Methylation, Hypermetyhlation
Background
Microsatellites, short tandem DNA repeats, are among
the most variable loci in the human genome. They ex-
perience mutations in the copy number of their repeat
units at a rate of 10−3 to 10−7 per cell division [1, 2].
Most such mutations result from replication slippage
that escaped the proofreading activity of mismatch re-
pair systems [3]. To date, microsatellite instability – an
increased propensity of a microsatellite to suffer length-
altering mutations – has been linked to at least 40 mono-
genic disorders [4, 5]. Such instability is also commonly
observed in many cancers, including colorectal, gastric,
endometrial, ovarian, and breast cancer [6, 7]. Among
them, colorectal cancer, the third most commonly diag-
nosed cancer in the world, and the second leading cause
of cancer-related deaths in western societies [8, 9] shows
several phenotypically distinct subtypes. Of these, tumors
with microsatellite instable (MSI) phenotype are found in
at least 15 % of sporadic colorectal cancers, and almost all
hereditary colorectal cancers [10]. MSI tumors differ from
other tumors in their gene expression and methylation
patterns to a great extent [11–13].
Several studies reported gene expression changes associ-
ated with tandem repeat mutations in human carcinomas.
For example, a CAG tri-nucleotide repeat associated with
prostate cancer has been identified in the first exon of the
androgen receptor gene. Expansion of this repeat decreases
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gene expression, and increases disease incidence and
tumor aggression [14]. Another example involves muta-
tions in the promoter of the telomerase reverse tran-
scriptase (TERT) gene, which causes overexpression of
the gene, and is a key mechanism behind some types of
cancer [15]. In breast cancer, a dinucleotide CA-repeat
within the first intron of the epidermal growth factor
receptor (EGFR) gene correlates with the gene’s tran-
scription levels. Mutant alleles of the highly poly-
morphic 28 base pair long repeat in the downstream
region of the proto-oncogene HRAS1 significantly in-
crease disease susceptibility for many cancers, including
breast cancer, colon cancer, rectal cancer, bladder can-
cer, and leukemia [16].
Several studies of colorectal adenomas showed that tu-
mors with mutations in different genes have distinctive
expression and methylation patterns [13, 17, 18]. The
patterns detected from such large-scale gene expression
data sets are being used to stratify colorectal tumor sub-
types [17, 19]. A study on comparability of gene expres-
sion changes in colorectal cancer, based on data produced
in various laboratories, showed that on average 95 % of
genes show consistent gene expression changes between
two major subtypes of colorectal cancer, independent of
the data source [20]. Despite many studies on colorectal
cancer, current therapeutic approaches cure only a frac-
tion of patients [10, 21], which necessitates a more
complete understanding of the kinds of mutations that
contribute to tumorigenesis and their impact on tumor
phenotypes. Although copy number variations of long
DNA stretches, and single nucleotide polymorphisms have
received much attention in colorectal tumors [13, 22], a
genome-wide analysis of tandem repeat instabilities is cur-
rently not available. Most work on repeat instability in
colorectal cancer focuses on variation between tumor and
matched normal genomes in merely five marker repeats
[23], a tiny fraction of the more than 3 million human
microsatellite loci [24, 25]. Recent advances in next gener-
ation sequencing and accurate repeat genotyping algo-
rithms enabled us to investigate repeat variation in tumor
genomes more comprehensively, and to study their poten-
tial consequences on gene expression.
Here we analyze tandem repeat variation in 35 colo-
rectal tumors and their matched normal genomes in
proximal (near-gene) promoter regions and exons of
18,439 genes, as well as in a smaller subset of genes in
known cancer-associated pathways. We find that MSI
tumors are significantly enriched for de novo repeat gain,
repeat loss, and copy number variation in their exonic
and promoter regions. Also, tumors, in general are
enriched in genes with such repeat instabilities com-
pared to normal tissues. We observe that genes with re-
peat instability in their promoters tend to be expressed
at lower levels. The promoters of genes in most well-
studied cancer pathways, including the p53 and Wnt
signaling pathways, are significantly enriched in un-
stable repeats, and those pathway genes with unstable
repeats show gene expression alterations consistent
with their role in carcinogenesis, whether oncogenic or
tumor-suppressive.
Results
Abundant repeat gains and losses in tumors compared to
normal genomes
We identified genes with tandem repeats in the exons
and promoters of 18,439 genes in 35 colorectal tumors
and their matched normal genomes (see Methods and
Additional file 1: Table S1 and S2). We found that a
tumor genome has on average 1510 exon sequences and
4192 promoters with tandem repeats. A normal genome
has on average 1475 exons and 4165 promoters with
tandem repeats.
A mean number of 1043 (one standard deviation: ±337)
genes in a tumor genome show repeats that do not occur
in the same gene’s promoter in the matched normal gen-
ome, compared to a mean number of 1016 (±334) pro-
moter repeats that are specific to normal genomes and do
not occur in tumor genomes. In total, there are 2059
(±373) genes that either lost a repeat or gained a de novo
promoter repeat in a tumor compared to their matched
genes in normal genomes. For brevity, we refer to these
repeats as orphans. Based on several indications of an MSI
phenotype reported in [13], we classified four tumors in
our data set as MSI (see Methods and Additional file 1:
Table S2). These tumors showed a slightly but non-
significantly higher number of genes with orphan repeats
(2072 ± 376; P not significant; Wilcoxon Rank Sum (WRS)
test; [26]). We then compared the number of promoters
with orphan repeats in the tumor-normal pairs to that of
normal genome pairs, based on all possible 595 paired
combinations of available normal genomes, and found
that significantly fewer genes in healthy tissues contain or-
phan repeats (1274 ± 481, P < 10−16, Fig. 1a).
A similar analysis on exonic repeats revealed that there
are, on average, 759 (±372) repeats in a tumor genome
that do not occur in the same gene in the matched nor-
mal genome, compared to a mean number of 725 (±290)
exonic repeats that are specific to the normal genomes
and do not occur in the tumor genomes. In total, we
found 1320 (±562) genes with orphan repeats in tumor-
normal genome pairs, and their number was much
higher in MSI tumors (2346 ± 841, P = 10−4). The num-
ber of genes with orphan repeats in tumor-normal pairs
was significantly smaller than in normal tissues (1090 ±
147, P = 0.01, Fig. 2a). Hence, as in promoters, repeats in
exonic regions experience gain and loss incidences more
frequently in tumors than in healthy tissues.
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More genes with unstable repeats in tumors
For those genes where both the tumor and matched nor-
mal genomes contain a repeat, we next asked how many
repeats are unstable, that is, varying in the copy number
of their repeat unit. Averaged over all 35 tumor-normal
genome pairs, the number of genes with unstable repeats
is 158 ± 24 (for MSI tumors only: 160 ± 22). This num-
ber is significantly greater than the number of genes
with unstable repeats in normal genome pairs (81 ± 19,
WRS test, P < 10−24, see Fig. 1b). When we repeated this
analysis for exonic repeats, we observed a similar enrich-
ment in repeats that varied in their copy number be-
tween the two sets of genome pairs. Specifically, we
found on average 36 ± 14 (for MSI tumors only: 40 ± 13,
P not significant) genes with unstable repeats in a
tumor-normal genome pair, a value greater than that in
a normal/normal pair (31 ± 12 genes, P = 0.04, see
Fig. 2b). We conclude that tumor genomes harbor more
repeat copy number variation than normal genomes
both in their promoters and exons.
Fig. 1 Significantly more promoters with orphan and unstable repeats in tumors. Box plots of the number of gene promoters a) with orphan
repeats b) with unstable repeats in normal-normal genome pairs (left boxes, n = 595) and in tumor-matched normal genome pairs (right
boxes, n = 35) in promoter sequences. Thick horizontal lines in each box mark the median, edges of boxes correspond to the 25th and
75th percentiles, and whiskers cover 99.3 % of the data’s range. The repeat incidences in each pair of boxes are significantly different from each other
within each panel (WRS Test, P < 10−16, P < 10−24, in panels a and b)
Fig. 2 Significantly more genes with orphan and unstable repeats in tumors. Box plots of the number of genes a) with orphan repeats b)
with unstable repeats in normal-normal genome pairs (left boxes, n = 595) and in tumor-matched normal genome pairs (right boxes, n = 35) in exons.
Thick horizontal lines in each box mark the median, edges of boxes correspond to the 25th and 75th percentiles, and whiskers cover
99.3 % of the data’s range. The repeat incidences in each pair of boxes are significantly different from each other within each panel (WRS Test,
P = 0.01, P = 0.04, in panels a and b)
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MSI genomes have more genes with repeat instability
In the previous analyses, we observed an enrichment in
the number of genes that contain unstable or orphan re-
peats in MSI tumors relative to microsatellite stable
(MSS) tumors. The differences were, however mostly
not significant due to the low number of MSI tumors.
To study in greater detail if the MSI phenotype of a
tumor genome can help explain differences in repeat in-
stability to its matched normal genome, we decided to
perform an analysis in which we consider genes that
have either unstable or orphan repeats (or both) as re-
peat instable. For this analysis, we first identified 11,016
genes whose promoters are instable by this criterion in a
tumor-normal pair. We found that MSI tumors have
more genes with repeat instability than MSS tumors
(2558 ± 274 and 2332 ± 364 genes, respectively, for pro-
moter regions, WRS test, P = 0.15; 2371 ± 840 and 1109
± 327, respectively, for exons, P = 0.003, see Fig. 3). We
repeated this analysis also for repeats whose repeat unit
consisted only of a single base (monucleotide repeats) to
find that the difference in the number of genes with repeat
instability between MSI and MSS genomes was now sig-
nificant also for promoters (55 ± 4, 45 ± 11, respectively,
for promoter region, P = 0.029 and 43 ± 28, 12 ± 7 respect-
ively for exons, P = 10−4).
Most cancer pathways in tumors are enriched for
unstable and/or orphan repeats in gene promoters
Many unique mutations in a cancer-associated signaling
pathway have similar functional effects on the pathway
[27, 28], which makes the analysis of entire pathways im-
portant to understand tumorigenesis. We focused on five
well-studied signaling pathways that play a central role
in carcinogenesis [13, 22]. These are the Wnt, TGF beta,
MAPK, mTOR, and p53 pathways (see Methods and
Additional file 1: Table S3). We identified 371 genes in
these five pathways, and will refer to them for brevity as
cancer genes. We first identified promoters of these
genes with tandem repeats and asked how many of them
contain orphan or unstable repeats. We found that in
the MAPK, p53, and Wnt signaling pathways, there were
significantly more genes with unstable repeats in their
promoters (after Bonferroni correction [29], WRS test,
P = 0.03, P < 10−8, P < 10−5, respectively, see Fig. 4a) be-
tween tumor-normal genomes compared to normal gen-
ome pairs. Similarly, in the MAPK, mTOR, p53, and
Fig. 3 MSI tumors have more genes with repeat instability. Box plots of the number of promoters with instability of a) any repeat, b)
mononucleotide repeats and the number of exons with instability of c) any repeat, d) mononucleotide repeats in MSI tumors (left
boxes, n = 4) and in microsatellite stable genome pairs (right boxes, n = 31). Thick horizontal lines in each box mark the median, edges
of boxes correspond to the 25th and 75th percentiles, and whiskers cover 99.3 % of the data’s range. The repeat incidences in each
pair of boxes are significantly different from each other within each panel except for the panel a (WRS Test, P = 0.029, P = 0.003, P = 10−4, in panels b, c
and d, respectively, after Bonferroni correction)
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Wnt signaling pathways, there were significantly more
genes with orphan repeats (after Bonferroni correction,
WRS test, P < 10−31, P < 10−24, P < 10−9, P < 10−18, re-
spectively, see Fig. 4b) between tumor-normal genomes
compared to normal genome pairs. Genes in the TGF
beta pathway contained only stable repeats and very few
orphan repeats both in the normal genome and the
tumor-normal genome pairs. Nevertheless, these find-
ings indicate that tumor genomes are overall enriched
for unstable and/or orphan repeats in most cancer-
associated signaling pathways.
An analogous analysis on exons revealed that only
the p53 pathway contains unstable or orphan exonic
repeats, whereas genes in the other pathways do not
show increased repeat instability. In addition, exons
in the p53 pathway are significantly enriched for or-
phan and unstable repeats (after Bonferroni correc-
tion, WRS test, P < 10−4, P = 0.03, respectively, see
Fig. 5). When we inspected the genes with repeats in
this pathway more closely, we found three genes with
both orphan and unstable genes in the tumor-normal
genome pairs, which do not contain any such repeat in
normal genome pairs. These genes are TP53I3, TP53I11
and CDKL1.
Genes with repeat instability are downregulated in
tumors
Next we asked whether repeat instability in tumors is as-
sociated with differential gene expression. More specific-
ally, we wondered if an acquired somatic repeat mutation
in a tumor can change a gene’s expression. Because the
Cancer Genome Atlas (TCGA) Data Portal [13] contains
RNA-seq based gene expression measurements mostly for
tumor tissues, we compared a gene’s expression in a tissue
where the gene acquired a repeat mutation (relative to the
matched normal tissue) with the gene’s expression in a tis-
sue where it did not acquire such a mutation. To this end,
we analyzed the 11,016 genes whose promoters contain
any of three possible instabilities (de novo repeat gain, re-
peat loss, or copy number variation) in at least one patient
(see Fig. 6). Subsequently, we retrieved gene expression
data for these genes in the 35 tumors [13]. For each gene,
we then computed the binary logarithm of the mean
Fig. 4 Gene promoters in most cancer pathways are significantly
enriched for repeat instability. Box plots of the proportion of promoters
in five different cancer-associated signaling pathways with a) unstable
repeats in their promoters and b) orphan repeats in their promoters,
for normal-normal genome pairs (left boxes, n = 595) and for
tumor-matched normal genome pairs (right boxes, n = 35). The
pathways are: MAPK (number of genes in the pathway, N = 113),
mTOR (N = 44), p53 (N = 98), TGF beta (N = 29), and Wnt (N = 87).
Thick horizontal lines in each box mark the median, edges of boxes
correspond to the 25th and 75th percentiles, and whiskers cover
99.3 % of the data’s range. In panel a repeat instability is significantly
different in tumor genomes for the MAPK, p53, and Wnt signaling
pathways (WRS test, P = 0.03, P < 10−8, P < 10−5, respectively, after
Bonferroni correction). In panel b repeat instability is significantly
different in tumor genomes for the MAPK, mTOR, p53, and Wnt signaling
pathways (WRS Test, P< 10−31, P< 10−24, P< 10−9, P< 10−18, respectively
after Bonferroni, correction)
Fig. 5 Exons in the p53 pathway are significantly enriched for repeat
instability. Box plots of the number of genes in the p53 pathway with
unstable repeats and orphan repeats in their exons, for normal-normal
genome pairs (left boxes, n = 595) and for tumor-matched normal
genome pairs (right boxes, n = 35). Thick horizontal lines in each
box mark the median, edges of boxes correspond to the 25th and
75th percentiles, and whiskers cover 99.3 % of the data’s range.
Repeat instability is significantly different between tumor and
normal genomes (WRS test, P = 0.03, P < 10−4, respectively, after
Bonferroni correction)
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expression level of the gene (i) in those genomes where
the gene has a repeat instability compared to the normal
tisssue and (ii) in genomes where the gene does not con-
tain an unstable or orphan repeat. We then asked if there
is a difference between the mean expression levels of these
genes, with the null hypothesis that the expression level of
a gene does not change when it acquires a somatic tandem
repeat mutation in a tumor tissue (Wilcoxon signed rank
(WSR) test [30]). We found that the mean expression
levels differ significantly (P < 10−350): Genes whose pro-
moters showed repeat instability were expressed at signifi-
cantly lower levels (see Fig. 7). Results of an analogous
expression analysis on exonic repeats also showed a slight
but significant (WSR test, P = 0.0015) decrease in gene ex-
pression for exons showing a repeat instability.
Pathway-specific gene expression alterations associated
with repeat instability
In the above analysis, we showed that genes with un-
stable repeats have significantly decreased expression
levels. Because we wondered whether this also holds for
each individual cancer pathway, we repeated our ex-
pression analysis for each pathway separately. To this
end, we first identified a set of gene promoters with re-
peat instabilities for each pathway. Next, for each gene
in a pathway-specific gene set, we computed the binary
logarithm of the mean expression level of the gene in
those genomes where the gene’s promoter shows repeat
instability and compared it to the expression level of
the same gene, but in genomes where the gene’s promoter
does not show repeat instability. Comparing these average
gene expression levels, we found that genes with tandem
repeat instabilities in their promoters are significantly
downregulated in the p53 pathway (WSR test after
Bonferroni correction for multiple testing, P < 10−4)
and overexpressed in the MAPK and Wnt signaling
pathways (P < 10−5, P = 0.03, respectively). In contrast,
genes in the TGF beta (P = 0.56) and the mTOR (P = 0.77)
pathways did not show any significant difference (see
Fig. 8). We repeated this analysis with exons in the p53
pathway, because it is the only cancer pathway that con-
tained unstable or orphan repeats in the exonic sequences.
We observed slightly decreased levels of gene expression,
when a gene in this pathway contains unstable or orphan
repeats, but the difference was not significant (P = 0.25).
Discussion
Here we present a comprehensive analysis of exome and
whole genome sequencing data from 35 patients with
colorectal cancers to identify tandem repeat instabilities
and their association with gene expression alterations.
To our knowledge, this is the first genome-wide analysis
Fig. 6 Schematic illustration of the expression analysis of genes with and without repeat instability. A gene (A, B, C and so on, where n = 18,439)
is shown in solid black, if it does not contain any repeat instability (repeat copy number variation, repeat gain, or repeat loss) in its promoter or
its exons between tumor and matched normal genomes of a patient (n = 35). It is shown cross-hatched if it contains at least one of these repeat
instability types. Only genes with a repeat instability in at least one of the patients are considered for this expression analysis (n = 11,016 genes
for promoter repeats, and n = 7531 genes for exonic repeats). For each gene, we computed (i) the mean of its expression level in tumors where
the gene shows repeat instability (cross-hatched arrow indicating transcription) and (ii) the mean of its expression in tumors where the gene does
not show repeat instability (solid black arrow indicating transcription). We then performed a WSR test to compare the mean expression values
between these two groups of genes, the null hypothesis being that the expression level of a gene is not associated with mutations in its tandem
repeat in a tumor tissue
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of tandem repeat instabilities in the currently largest col-
lection of colorectal tumor genomes. To date, there are
few other studies on genome-wide tandem repeat muta-
tions in cancers. One such study [31] genotyped repeat
variations in breast cancer exomes in comparison to ran-
dom healthy individual tissues. Another study [7] focuses
on microsatellite mutations within various tumors (includ-
ing colorectal cancer) in a small number of genes (137).
Our study remains unique in its focus on comparison be-
tween tissues from the same individual.
Using the matched tumor and normal tissues, we
identified two types of repeat instability between these
pairs of genomes, namely (i) repeat copy number vari-
ation, and (ii) de novo gains and losses of repeats. We
identified these instabilities both in promoter regions
and exons of 18,439 human genes, and in a smaller set
of 371 genes from five signaling pathways associated
with cancer. We found evidence for enhanced repeat
instability in promoters and exons of tumor tissues. We
also showed for the first time that tumor genomes with
an MSI phenotype, which indicates a defect mismatch
repair system, contain more repeat instabilities than
microsatellite stable tumors. The difference was more
pronounced when we focused on mononucleotide re-
peats, in agreement with the finding that replication
slippage alone cannot explain the incidence of polymor-
phisms in repeats whose repeat units are longer than
one nucleotide [32]. Although replication slippage is a
major factor driving mononucleotide repeat variation, add-
itional cellular factors, such as chromatin reorganization
[33] and telomere instability [34] also play a role for non-
mononucleotide repeats.
Motivated by the impact of gene regulatory alterations
on carcinogenesis, we studied repeat-associated gene ex-
pression changes. Using the comprehensive catalogue of
information we retrieved from [13], we compared a gene’s
expression level in genomes where the gene shows repeat
instability and where it does not. We observed that genes
with repeat instability are mostly downregulated, and es-
pecially so if this instability occurred in the promoter, em-
phasizing the importance of regulatory mutations in
carcinogenesis also suggested by others. Two other
studies [15, 35] identified recurrent mutations in gene
promoters and their association with gene expression
levels in multiple tumor genomes across many cancer
types. Another study on non-coding disease associated
variants [36] showed that these variants are concentrated
in regulatory DNA marked by DNase hypersensitive sites
and that these variants perturb epigenetic processes.
Fig. 7 Genes with repeat instability are downregulated. Box plot of
binary logarithm of mean expression levels of those genes with repeat
instability (copy number variation, repeat gain, or repeat loss) (left box)
and of genes without repeat instability (right box) in tumor genomes.
Thick horizontal lines in each box mark the median, edges of boxes
correspond to the 25th and 75th percentiles, and whiskers cover
99.3 % of the data’s range. The difference in gene expression is
significant (WRS Test, P < 10−350, n = 11,016)
Fig. 8 Genes with repeat instability are dysregulated in the Wnt, MAPK
and p53 pathways. Box plot of binary logarithm of mean expression
levels of those genes with repeat instability (copy number variation,
repeat gain, or repeat loss) (left box in each pair) and of genes without
repeat instability (right box) in tumor genomes, for genes in the Wnt
(n = 32, for both boxes), TGF beta (n = 6), MAPK (n = 19), mTOR (n = 38)
and p53 (n = 31) signaling pathways. Thick horizontal lines in each
box mark the median, edges of boxes correspond to the 25th and
75th percentiles, and whiskers cover 99.7 % of the data’s range.
Differences in gene expression are significant for the p53 (WSR test
after Bonferroni correction P < 10−4), MAPK (P < 10−5) and Wnt
signaling pathways (P = 0.03)
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Gene silencing mediated by repeats is a phenomenon
observed in various diseases, where, for example, DNA
around tandem repeats becomes heterochromatic, leading
to decreased promoter accessibility and hence to local
transcription repression. This phenomenon has been doc-
umented in mammalian embryonic carcinoma cells [37],
as well as for repeat-induced diseases such as myotonic
dystrophy and Friedreich’s ataxia [38]. Apart from chro-
matin reorganization, promoter hypermethylation, which
is commonly observed in carcinogenesis [18, 39, 40], can
also cause gene silencing or reduced gene expression.
Several genes are downregulated via promoter hyper-
methylation in colon cancers [39, 41]. This type of
downregulation can act synergistically with other gen-
etic mechanisms, such as somatic mutations, to alter
key signaling pathways critical to colorectal tumori-
genesis [39, 42]. Previous smaller-scale studies based
on the five markers characterized in the “Bethesda
guidelines” microsatellites [23] showed an association
between promoter hypermethylation and microsatellite
instability [43, 44]. We therefore asked if promoters with
repeat instability show higher promoter methylation
levels, and found indeed a small but significant increase
of methylation in promoters with unstable repeats
(WSR test, P = 0.004, see Methods and Additional file 2:
Figure S1). Our findings reveal, for the first time, a
genome-wide association between promoter methylation
and decreased expression in genes with repeat instability.
Although identification of mutated cancer genes pro-
vides insights into tumorigenesis [45], diverse and func-
tionally heterogeneous genes can be mutated even
within same type of tumor [27, 28]. However, some
pathway dysregulations are shared among multiple can-
cer types [22, 27, 46]. We therefore identified unstable
repeats in the promoters of genes in five prominent
cancer-associated pathways. One of them is the Wnt
signaling pathway, which is commonly implicated in
carcinogenesis due to its regulatory role in cell prolifer-
ation, gene transcription and cell migration [13, 47].
Colorectal cancers of all subtypes almost invariably start
with an activating mutation in this pathway [22, 48]. Re-
markably, we found that gene promoters in the Wnt path-
way are significantly enriched for unstable and/or orphan
repeats, and these genes are also significantly overex-
pressed (in contrast to the opposite genome-wide trend
discussed above). Genes in the MAPK pathway, a signal-
ing cascade that regulates cellular transcription and trans-
lation levels [27], also show higher repeat instability in the
promoters of tumor-normal genome pairs than of normal
genome pairs, and those promoters with unstable and/or
orphan repeats are also significantly overexpressed. This
increase in gene expression is in line with the significant
hyperactivation of the MAPK pathway revealed by a com-
prehensive study on colorectal tumors by TCGA [13]. In
contrast, none of the genes in the TGF beta pathway show
increased repeat instability or expression alterations that
are associated with repeat instability. This observation is
in line with the previous observation [13] that this path-
way is the least divergent pathway between colorectal tu-
mors and their matched normal genomes in terms of gene
copy number variation and gene expression.
The final pathway we analyzed is the p53 pathway. It
plays a crucial role in the cell cycle and can initiate cell
death [49]. Inactivation of the p53 pathway through
multiple mutations is an almost universal feature of hu-
man cancer cells [50, 51]. In agreement with its central
role in tumor suppression, we found that genes in this
pathway are significantly enriched both for promoter
and exonic repeat instabilities in tumor-normal pairs
compared to normal genome pairs, and genes with in-
stabilities both in promoter and exon sequences are
downregulated in colorectal tumors. When we exam-
ined pathway genes with exonic repeats, we identified
several genes with unstable and/or orphan repeats in
tumor-matched normal genome pairs but not in normal
genome pairs. One of them, TP53I3 is a well-known ex-
ample for tandem repeat instability associated with can-
cer. It has been shown that this gene contains a
pentanucleotide (TGCCC) repeat where the tumor-
suppressor p53 binds to activate the gene, a mechanism
suggested to be mediating cell death [52]. Copy number
variation in this repeat alters TP53I3 activation and
probably affects an individual’s susceptibility to cancer
[53]. We show for the first time that this repeat is actu-
ally polymorphic in a tumor tissue. We also identified
two other genes (TP53I11 and CDKL1) that contain
tumor-specific repeat instabilities in their exons, and
where repeat instability had not been documented so
far. These findings highlight the importance of analyz-
ing tumor-specific tandem repeat instability, and their
consequences on gene regulation, which could contrib-
ute to carcinogenesis.
Among the limitations of our study is that we cannot
distinguish between somatic and germline mutations.
This is relevant, because some mismatch repair genes
can experience germline mutations that cause colorectal
cancer [10]. These germline mutations can also play a
role in forming different subtypes of colorectal cancer,
as they trigger accumulation of different sets of somatic
mutations throughout carcinogenesis [22]. However, be-
cause 90 % of cancer mutations are somatic [45], this is
not a serious drawback. Second, an ideal control analysis
would compare repeat instability between normal-normal
genome pairs from healthy tissues of the same individual
to those of tumor-normal genome pairs. However, the ne-
cessary multiple normal genomes are currently not avail-
able, which is why we had to compare the genomes of
normal tissues from different individuals as a control. As a
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result, we may underestimate differences in repeat in-
stability between normal and tumor genomes. Another
source of underestimating repeat number and instability is
our conservative approach of identifying matched repeats
(see Methods). Absent these limitations, we might see an
even greater excess of unstable repeats in colorectal tu-
mors. Some of them would be by-products of defective
mismatch repair, whereas others might trigger or promote
carcinogenesis. It is also important to note that our cancer
gene set is unlikely to encompass all genes that may play a
role in cancer, because we focused on particular, well stud-
ied cancer associated pathways. Finally, limitations in
whole genome alignment quality may underestimate re-
peat copy number variation in gene promoters.
Conclusions
Because genetic instability is not only central to tumor
pathogenesis, but may also underlie the development of
resistance to chemotherapeutic agents, it is important to
identify its incidence and phenotypic consequences. Our
analysis, based on the best currently available data sets is
a first small step towards this understanding. Future
studies using more data and more advanced technologies
will enhance this understanding further, in order to de-
velop more effective molecular diagnostic approaches
centered on repeat instability. For example, studies com-
paring gene expression levels between tumor and healthy
tissues will be able to identify tumor-specific gene expres-
sion alterations more confidently. Also, information on
allele-specific expression can help explaining the asso-
ciation between repeat instability and downregulation.
Future studies with a more comprehensive set of micro-
satellite stable tumors will hopefully disentangle differ-
ences between microsatellite-stable and -unstable tumors
in greater detail. Finally, differentiating between clonal
and subclonal instabilities will facilitate a better under-
standing of the life histories of tumors, because they show
extreme intra-tumor heterogeneity [54–56].
Methods
Genome sequence analysis
We obtained whole genome sequences of colon and rectal
tumors, together with their matched genomes – the same
individual’s genomic sequences from blood samples –
from the controlled access data tier of the Cancer Genome
Atlas Data Portal (TCGA, http://cancergenome.nih.gov/,
[13]). For our analysis, we considered only genomes for
which RNA-Seq data were also available in TCGA. The
genome sequence data is based on 2-5X coverage Illumina
HiSeq2000 sequencing of 80–100 million pairs of 100-
nucleotide-long reads, aligned against human genome
build #18 [13] with the indel-compatible software package
BWA (bwa-0.5.9rcl [57]). For the exon analysis, we used
Illumina exome-seq data exceeding 20X coverage for
~44Mbs of sequence from ~30 K genes.
We generated consensus sequences for the promoters
and exons of genes in the tumors and their matched
normal genomes using SAMtools [58]. In order to spe-
cify the exonic regions, we considered all transcript vari-
ants for each gene in the human reference genome
annotation [59] for human genome build #18. We ex-
cluded those exons that contained transcript variants in
more than one chromosome, such as transposons. For
genes with multiple transcripts, we merged all exonic re-
gions from all transcripts into one super-transcript. Be-
cause our previous work on human tandem repeats [60]
suggests that the 5,000 base pairs [bps] upstream from the
transcription start site contain the most regulatory signals,
we focused on this region and refered to it as the promoter.
While generating our consensus sequences, we noticed
that some genomes contained many more unaligned se-
quences than others. We eliminated genomes with un-
aligned nucleotides in more than 10 % of the regions of
our interest (promoters or exons), which reduced our data
set to 35 genomes (see Additional file 1: Table S2 for a list
of genomes). We considered a tumor MSI, if its MSI sta-
tus was MSI-H based on [13]. Because this approach
yielded only three genomes, we considered also other cri-
teria of an MSI phenotype, as provided by [13]. We found,
however, only one more genome that was not MSI-H but
showed all other indications of an MSI phenotype, namely
a CIMP-H methylation subtype, MLH1 silencing, and a
MSI-CIMP expression subtype. We therefore considered
this genome also MSI (see Additional file 1: Table S2).
After removing genes from the data set whose promoters
or exons could not be aligned, we focused our analysis on
the remaining “global” set of (one-to-one homologous)
18,439 genes (see Additional file 1: Table S1), as listed in
[13]. Apart from analyzing this global set, we also per-
formed a more detailed analysis of 371 cancer genes
(Additional file 1: Table S3) that fall into five well-
studied cancer associated pathways [13, 22, 28].
Tandem repeat identification
We used the program Tandem Repeat Finder 4.07b [61]
to identify tandem repeats in the consensus sequences.
Specifically, we identified repeats with (i) an incidence of
indels (insertions or deletions) in adjacent repeat units
below 10 % (e.g., a repeat unit of 20 nucleotides can have
up to two single base pair indels relative to the consen-
sus pattern, which is the repeat unit most common in
the whole repeat sequence [61]), and (ii) a sequence
identity of repeat units above 90 % (e.g., at least 18 nu-
cleotides of a repeat unit of 20 nucleotides must match
the consensus pattern). We set the Tandem Repeat
Finder Score to a value of 80, as we were most interested
in how repeat variation might cause gene expression
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differences, and variation of tandem repeats increases
strongly for repeats of high Tandem Repeat Finder Scores
[62]. We considered both micro- and minisatellites with
tandem repeat units up to 100 nucleotides in length. Re-
peats longer than that are more stable and therefore less
likely to cause gene expression differences [62].
To identify repeat gains and losses, we first defined
matched repeats between a tumor and its normal genome.
These are repeats with the same repeat unit that occur in
the promoter or exon of the same (homologous) genes in
a tumor and its matched normal genome. We did not
consider gene families separately. We allowed positional
variation of repeats up to 50 nucleotides within a pro-
moter or an exon, because indels can cause substantial
shifts in repeat location even within a species [63].
To find out whether a tumor genome shows a signifi-
cant difference in repeat incidence or variability to a
normal genome, it is necessary to compare (i) the inci-
dence or variability of repeats in a tumor genome rela-
tive to its matched normal genome to (ii) the incidence
or variability of repeats between two normal genomes.
We computed the latter from our 35 normal genomes
by pairing them in all possible (595) combinations, com-
puting our measures of repeat incidence and variability
for each pair, and pooling the resulting data.
Gene expression analysis
The gene expression data we used is based on RNA se-
quencing of 350–450 base pair-long Illumina Cluster
Station and Genome Analyzer reads by TCGA [13]. The
data comprises expression levels in reads per kilobase of
transcript per million reads mapped (rpkm) for 18,439
genes in the 35 tumor genomes we analyzed.
Methylation analysis
The promoter methylation data we used is based on Illu-
mina Infinium HumanMethylation27 arrays to profile
DNA methylation at gene promoters of TCGA [13], target-
ing 27,578 CpG sites located in proximity to the transcrip-
tion start sites of 14,475 consensus coding sequencing
(CCDS) in the NCBI Database (Genome Build 36). We
computed for each gene the methylation level in those ge-
nomes where the gene has a repeat instability in its pro-
moter, and compared it to the gene’s methylation level in
genomes where the gene has no repeat instability.
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